News

Public · Published

Inovio Gets Accelerated FDA Approval of Voceryq; Shares More Than Triple After Hours

Inovio Pharmaceuticals said the FDA granted accelerated approval for Voceryq to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. The drug was previously known as INO-3107. Inovio expects orders and shipping in about 60 days, with a full commercial launch in the first quarter of 2027. Shares more than tripled after hours to $2.17.

Published:

Updated:

What happened

Inovio Pharmaceuticals said the FDA granted accelerated approval for Voceryq to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. The drug was previously known as INO-3107. Inovio expects orders and shipping in about 60 days, with a full commercial launch in the first quarter of 2027. Shares more than tripled after hours to $2.17.

Confirmed

Global impact / market context

Approval gives Inovio a route to sell Voceryq for the stated use, while the expected ordering and shipping date sets a near-term step toward revenue. A full launch is not expected until early 2027, so sales timing and uptake remain uncertain.

Analyst inference

Shares more than tripled after hours to $2.17 following the approval announcement. That sharp move reflects the reported immediate share-price response, but the article gives no sales forecast, launch costs, or evidence of sustained demand to show how commercial results may develop.

Confirmed

What to watch

  1. Whether Voceryq becomes available to order and ship in about 60 days, as Inovio expects; delays would push back the first opportunity for product sales. Analyst inference
  2. Whether the full commercial launch occurs in the first quarter of 2027, the timetable Inovio stated for broader commercial availability. Proposed
  3. Whether reported use to reduce surgery frequency translates into demand and revenue; the article provides no sales estimates or uptake figures. Analyst inference

Evidence

  • Original source link unavailable